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Introduction: A key phenomenon in rheumatoid arthritis is the formation of lymphoid follicles in the inflamed
synovial membrane. C-X-C motif chemokine 13 (CXCL13) is central in this process as it attracts C-X-C chemokine
receptor type 5 (CXCR5)-expressing B cells and T follicular helper cells to the follicle. We here examine the role of
CXCL13 and its association with disease in patients with treatment-naïve early rheumatoid arthritis.
Methods: Plasma samples from patients in the OPERA trial were examined for CXCL13 at treatment initiation and
after 6 months of treatment with either methotrexate plus placebo (DMARD) (n = 37) or methotrexate plus
adalimumab (DMARD + ADA) (n = 39). Treatment outcome was evaluated after 1 and 2 years. CXCL13 plasma levels
in healthy volunteers (n = 38) were also examined.
Results: Baseline CXCL13 plasma levels were increased in early rheumatoid arthritis patients in comparison with
healthy volunteers. Also, plasma CXCL13 correlated positively with disease activity parameters; swollen joint count
28 (rho = 0.34) and 40 (rho = 0.39), visual analog score (rho = 0.38) and simplified disease activity index (rho = 0.25)
(all P <0.05). CXCL13 levels decreased a significantly twofold more in the DMARD + ADA group than in the DMARD
group. Baseline CXCL13 plasma levels in the DMARD group correlated inversely with disease activity parameters;
disease activity score in 28 joints, four variables, C-reactive protein based (DAS28CRP) (rho = 0.58, P <0.05) at 12
months. High baseline CXCL13 was associated with remission (DAS28CRP less than 2.6) after 2 years.
Conclusions: In treatment-naïve early rheumatoid arthritis patients, plasma CXCL13 levels were associated with joint
inflammation. Furthermore, patients with high baseline plasma CXCL13 levels had an improved chance of remission
after 2 years. We propose that high CXCL13 concentrations indicate recent onset of inflammation that may respond
better to early aggressive treatment. Thus, high levels of CXCL13 could reflect the ‘the window of opportunity’ for
optimal treatment effect.
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Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease with joint inflammation and autoantibody production
as key elements of its pathogenesis. The course of the dis-
ease is still difficult to predict. The encouraging results of
early, intensive treatment of RA suggest the existence of a
‘window of opportunity’ during which effective therapy can
induce long-lasting remission [1]. Unfortunately, it is not
known when this ‘window of opportunity’ is open, and the
search for informative biomarkers of early inflammation
and triggers of memory development therefore becomes a
pertinent issue in RA research.
T cells are present in elevated numbers in the synovial
joints in RA where they form cellular infiltrates that re-
semble ectopic lymphoid aggregates with germinal center
formation [2]. This suggests the presence of an ongoing
antigen presentation and follicle formation in the syno-
vium. The follicle is a well-organized structure, generated
by follicular dendritic cells (FDCs), B cells, and follicular
helper CD4 T (TFH) cells. Within the follicle, B cells are
activated and matured into long-lived plasma cells, which
secrete high-affinity antibodies [3]. The production of
autoantibodies is central in RA [4], and the processes lea-
ding to follicle formation in the RA synovium are there-
fore of great interest. The central role of ongoing immune
activation in RA development is further supported by the
fact that CTLA4 treatment reduces disease activity [5].
The chemokine C-X-C motif chemokine 13 (CXCL13) is
necessary for follicle formation and is constitutively ex-
pressed in secondary lymphoid tissue, primarily by FDCs
[6]. Further, CXCL13 expression is upregulated by tumor
necrosis factor alpha (TNFα) and by T cell receptor stimu-
lation [7,8]. C-X-C chemokine receptor type 5 (CXCR5),
the only known receptor for CXCL13, is expressed by
naïve B cells and TFH cells, and it controls the migration
of these cells to the follicle [9]. The CXCL13-CXCR5 axis
is critical to the generation of immunological memory
based on long-lived plasma cells because the interaction
between TFH and B cells is necessary for the formation of
plasma cells and autoantibody production [7,10]. Recently,
CXCL13 has risen to be a possible new marker of disease
and inflammation in RA. CXCL13 is reported upregulated
in RA patients, and is suggested to be connected with both
disease activity and rheumatoid factor [11,12].
In this study, we aim to investigate CXCL13’s asso-
ciation with markers of disease activity in patients with
early RA, who participated in a double-blind randomized
clinical trial of two different treatment regimes.
Materials and methods
Collection of patient samples and clinical data
A longitudinal set of plasma samples was obtained from a
randomly selected subset of patients (n = 76, age = 55.4
(52 to 59), 72% women) who participated in the OPERAstudy (OPtimized treatment algorithm in Early Rheumatoid
Arthritis). The trial was conducted in accordance with the
Declaration of Helsinki and approved by the Danish
Medical Agency (2612–3393), the Danish Data Protection
Agency (2007-41-0072) and the Regional Ethics Com-
mittee (VEK-20070008). All patients gave written consent
to participate in the study. The study design has been de-
scribed in detail elsewhere [13]. Briefly, the patients were
early treatment-naïve RA patients whose symptoms had
lasted less than six months. Upon entry into this double-
blind study, patients were randomized to conventional
methotrexate (MTX) treatment plus placebo (disease-
modifying anti-rheumatic drug (DMARD)) or MTX in
combination with adalimumab (DMARD + ADA); both
regimes were given in combination with intra-articular
triamcinolone injections. If patients experienced a flare in
disease, treatment was optimized. In relation to a change
in treatment regime, the patients received intra-articular
triamcinolone injections. Different treatment regimes are
described in details in the original study [13]. In the
present study, we used plasma samples obtained before
the initiation of treatment (baseline) and after 6 months of
treatment. At baseline, immunoglobulin M-rheumatoid
factor (IgM-RF) and anti-citrullinated protein antibody
(anti-CCP) were assessed. Disease activity was assessed
each time plasma samples were collected using C-reactive
protein (CRP), number of swollen (SJC 28 and 40) and
tender joints (TJC 28 and 40), and physician’s global as-
sessment of disease activity measured by a visual analog
scale (VAS physician global), simplified disease activity
index (SDAI), the disease activity score in 28 joints
(DAS28CRP, four variables, CRP-based) and total Sharp
Score (TSS). After the first year of treatment, adalimumab
was discontinued and patients were continuously followed
and treated for disease flare. DAS28CRP <2.6 was defined
as remission. The patients’ clinical characteristics are pre-
sented in Table 1. Plasma samples were also collected
from gender- and age-matched healthy volunteers (HVs)
(n = 38, age median 54.8 (38 to 62), 67% women).
ELISA
Plasma CXCL13 levels were quantified according to the
manufacturer’s instructions using a commercially available
sandwich enzyme-linked immunosorbent assay (ELISA)
kit (Quantikine human CXCL13/BCL/BCA-1, #DCX130
R&D systems, Minneapolis, MN, USA). All samples were
diluted 1:2 in Calibrator Diluent RD6-41 supplemented
with mouse and bovine IgG to ensure preaggregation of
heterophilic antibodies. Samples were analyzed in dupli-
cates, and the minimum detection limit (cutoff) was cal-
culated as two standard deviations of the blanks. Values
below the cutoff value were assigned the same value as
the cutoff. The ELISA kit was validated as previously de-
scribed by Kragstrup et al. [14].
Table 1 Patient characteristics
Baseline 6 months
DAS28CRP 5.7 (5.1-6.5) 2.1 (1.8-2.8)
Swollen joint count (0-28) 10 (7.0-17) 0 (0-0)
Tender joint count (0-28) 12 (7.0-18) 0 (0-1.3)
Swollen joint count (0-40) 13 (9.0-22) 0 (0-0)
Tender joint count (0-40) 17 (11-26) 0 (0-3.0)
VAS doctor global (0-100 mm) 56 (41-73) 2.0 (0-10)
CRP (mg/ml) 15 (7.0-42) 7.0 (7.0-7.0)
SDAI (0.7-82) 37 (29-47) 3.1 (0.86-7.0)
IgM-RF (% positive) 70.7% -
Anti-CCP (% positive) 62.7% -
TSS (% positive) 17.3% -
Relevant disease markers at baseline and following 6 months of treatment.
Data are expressed as median with interquartile range (IQR). Anti-CCP: anti-
citrullinated protein antibody; CRP: C-reactive protein; DAS28CRP: disease
activity in 28 joints, four variables, C-reactive protein based; IgM-RF: IgM
rheumatic factor; SDAI: simple disease activity index; TSS: total Sharp score;
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Statistical analyses were performed using GraphPad
Prism 5.0 for Mac (GraphPad Software, Inc., La Jolla,
CA, USA). ELISA data were analyzed using the Mann-
Whitney U test for nonpaired data and the Wilcoxon
matched pairs test for paired data. Data are expressed as
median with interquartile range (IQR). Nonparametric
paired data were assessed for statistical correlation using
Spearman’s rho. In all tests, the level of significance was
a two-sided P value of less than 0.05.RA
Figure 1 Plasma levels of CXCL13 in early RA patients and
healthy volunteers. Levels of CXCL13 in plasma from early-stage
RA patients (n = 76) and healthy volunteers (n = 38). Plasma CXCL13
levels were measured at treatment initiation (0) and after 6 months
of treatment (6). Bars represent median with interquartile range.
The cutoff level for detection was 7.8 pg/ml (dotted line). All values
below the cutoff were assigned the cutoff value. Level of significance
is indicated by asterisks (***: P <0.0001). CXCR13: C-X-C chemokine
receptor type 13; RA: rheumatoid arthritis.Results
Plasma levels of CXCL13 in early RA
In patients with early RA plasma levels of CXCL13 at
baseline were median (149.3 pg/ml (range 74.8 pg/ml
to 245.0 pg/ml)). After 6 months of treatment plasma
CXCL13 decreased threefold to 48.1 pg/ml (26.9 pg/ml to
93.0 pg/ml), P <0.001. CXCL13 levels at 6 months were
similar to those observed in HVs (50.3 pg/ml (29.2 pg/ml
to 92.7 pg/ml)) (Figure 1).Additional adalimumab treatment resulted in a greater
degree of CXCL13 inhibition
We assessed plasma CXCL13 levels in the two treatment
groups separately. At baseline, the plasma CXCL13 levels
in the DMARD + ADA group were not significantly dif-
ferent from the plasma CXCL13 levels in the DMARD
group. Although the plasma CXCL13 levels in both groups
after 6 months of treatment did not differ from those of
HVs, they were reduced 4.2-fold in the DMARD + ADA
group, but only 1.9-fold in the DMARD group (P <0.05)
(Figure 2).CXCL13 was associated with core disease parameters
We analyzed the association between CXCL13 levels and
clinical disease activity parameters at baseline and after 12
months of treatment. At baseline, CXCL13 plasma levels
correlated positively with SJC28 (rho = 0.336, P = 0.003)
and SJC40 (rho = 0.392, P = 0.001) (Table 2). It also cor-
related with VAS physician global (rho = 0.378, P = 0.001)
and SDAI (rho = 0.254, P = 0.028) (Table 2). CXCL13 level
at baseline showed no association with clinical disease ac-
tivity parameters after 12 months of treatment (Table 2).
At six months, we neither observed associations between
plasma CXCL13 levels and the disease activity parameters,

















Figure 2 Change in CXCL13 plasma levels in the two treatment
groups. Lines represent the median decrease in plasma CXCL13
levels from 0 to 6 months, in the DMARD + ADA (full line) and
DMARD (dotted line) groups. *Indicates a statistically significant
difference between the changes in the two groups (P <0.05). ADA:
adalimumab; CXCR13: C-X-C chemokine receptor type 13; DMARD:
disease-modifying anti-rheumatic drug.







Swollen joint count 28
Tender joint count 28
Swollen joint count 40






Swollen joint count 28
Tender joint count 28
Swollen joint count 40





Correlations of clinical data with the plasma level of CXCL13 measured at 0 months
presented as Spearman’s rho (P value). P values lower that 0.05 are considered stati
between plasma CXCL13 level and disease parameters were observed at baseline, b
CXCR13: C-X-C chemokine receptor type 13; CRP: C-reactive protein; DAS28CRP: dis
rheumatic factor; OPERA: OPtimized treatment algorithm in Early Rheumatoid Arthr
analog scale.
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correlation with TSS at any time point.
High baseline CXCL13 in the DMARD-treated group was
associated with low SDAI and VAS score at one year
Since CXCL13 plasma levels varied widely at baseline, we
aimed to identify subgroups within the cohort. We divided
the patients into two groups according to their CXCL13
plasma levels at baseline with CXCL13-high >100 pg/ml
and CXCL13-low <100 pg/ml as described by Rosengren
et al. [11]. Treatment induced no significant change in
CXCL13 plasma levels in the CXCL13-low group, but a
significant decrease was seen in the CXCL13-high group
(Figure 3). Scrutiny of the CXCL13-high DMARD group
revealed that the baseline CXCL13 level had a significant,
negative correlation with a range of variables reflecting
disease activity at 12 months: VAS doctor (rho = −0.598,
P = 0.003), CRP (rho = −0.504, P = 0.02), DAS28CRP
(rho = −0.582, P = 0.006), and SDAI (rho = −0.589,
P = 0.006). In the DMARD + ADA group, however, no
similar correlations with disease markers were observed.tivity parameters at baseline and following 6 months of
0 months rho (P) 6 months rho (P)
−0.112 (0.34) 0.073 (0.54)
0.021 (0.86) 0.099 (0.31)
−0.011 (0.92) 0.059 (0.62)
0.336 (0.003) 0.110 (0.35)
0.166 (0.16) 0.001 (0.99)
0.392 (0.001) 0.177 (0.13)
0.162 (0.17) 0.007 (0.95)
0.378 (0.001) 0.103 (0.38)
0.094 (0.42) 0.145 (0.21)
0.205 (0.078) 0.089 (0.45)
0.254 (0.028) 0.091 (0.44)
0.131 (0.27) −0.077 (0.51)
0.195 (0.096) −0.012 (0.92)
0.162 (0.17) −0.085 (0.47)
0.219 (0.060) 0.045 (0.71)
0.006 (0.96) −0.037 (0.76)
−0.047 (0.69) −0.124 (0.30)
0.059 (0.62) 0.012 (0.92)
0.009 (0.94) 0.047 (0.67)
and after 6 months of treatment, in the OPERA trial. Correlations are
stically significant (indicated by bold). Statistically significant correlations
ut not following treatment. Anti-CCP: anti-citrullinated protein antibody;
ease activity in 28 joints, four variables, C-reactive protein based; IgM-RF: IgM
itis; SDAI: simple disease activity index; TSS: total Sharp score; VAS: visual
Group: DMARD+ADA 





































































































Figure 3 Plasma CXCL13 at 0 and 6 months, in patients with high- and low-level CXCL13 in the treatment groups. Plasma levels of
CXCL13 at 0 and 6 months in the DMARD group, the DMARD + ADA group and all patients, subdivided into ‘CXCL13-high’ and ‘CXCL13-low’
according to baseline level of CXCL13 ≥100 vs. <100. ***Indicates P <0.001, **: P <0.01, and ns: P >0.05. ADA: adalimumab; CXCR13: C-X-C chemokine
receptor type 13; DMARD: disease-modifying anti-rheumatic drug.
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ween the CXCL13-high and -low group (data not shown).
Sustained remission after 2 years was associated with
high baseline CXCL13
We examined patients who were in remission
(DAS28CRP <2.6) at the 2-year follow-up (n = 48).
These patients had a high baseline CXCL13 level
(184.2 pg/ml (83.46 to 275.2)), whereas patients in
non-remission (DAS28CRP >2.6, (n = 25)) had a lower base-
line CXCL13 level (110.3 pg/ml (45.95-187.6), P = 0.014)
(Figure 4). When analyzed per randomization group, weobtained similar results for the DMARD + ADA group,
and additionally here, 89% of patients in remission were in
the CXCL13-high baseline group. In the DMARD group,
59% of patients in remission after two years were in the
CXCL13-high baseline group (data not shown).
We repeated the same analysis evaluating CRP <8 mg/L
at 2-year follow-up. Here, we observed no difference in
CXCL13 plasma level at baseline.
The OPERA is a treat-to-target protocol, where treat-
ment is optimized by intra-articular triamcinolon injec-
tions following a strict optimization protocol [13]. To





















Figure 4 Baseline CXCL13 stratified by clinical disease activity
score (+/−DAS28-remission) after 2 years of therapy. Both
treatment groups are considered together. Bars represent median
with IQR. *Indicates statistically significant difference (P = 0.03).
CXCR13: C-X-C chemokine receptor type 13; DAS28: disease activity
score in 28 joints; IQR: interquartile range.
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used the number of intra-articular injections between
baseline and two years, and we investigated if patients
had been receiving additional DMARDs than MTX
(hydroxychloroquine and/or sulphasalzine). Patients in
the CXCL13-high baseline group did not differ from pa-
tients in the CXCL13-low group in regard to change in
treatment regimes (Figure 5 and Table 3).
Discussion
In this study, we further investigated the role of CXCL13
in RA. We measured high CXCL13 plasma levels in early
DMARD-naïve RA patients. Six months of anti-rheumatic
treatment reduced plasma CXCL13 to levels observed in
healthy volunteers. We also showed that baseline CXCL13
strongly correlated with SDAI, VAS and joint involvement
at treatment initiation. These findings contribute to estab-
lishing a role for CXCL13 as a potential marker of inflam-
mation in early RA. Our findings are in line with earlier
published results on CXCL13 [11,15,16], but our study
provides new knowledge suggesting CXCL13 as a marker
of joint involvement in early RA.
CXCL13 is a pivotal chemokine in establishing an
adaptive immune response. It attracts B cells in thesecondary lymphoid tissue, which facilitates the gener-
ation of antibodies and local inflammation [6,7]. The ob-
served associations with joint involvement contribute to
establishing activity within the lymphoid follicle in early
RA as an important mechanism in the progression of
RA. Because CXCL13 is produced by synovial cells,
CXCL13 could serve as a marker that reflects local ac-
tivity and inflammation [8]. CXCL13 was not associated
with CRP or DAS28CRP. Rioja et al. [17] describes high
CXCL13 and DAS28 levels in patients with active vs. in-
active RA. In line with these findings, we observed that
CXCL13 levels are high in untreated early RA patients
(active RA), as is DAS28CRP and CRP. Treatment of
early RA reduces disease activity, and thereby also
DAS28CRP as well as CXCL13. Thus, although not asso-
ciated with CRP, CXCL13 remains a potential marker of
disease activity in early RA patients.
In the DMARD treated CXCL13-high group, the base-
line CXCL13 levels correlated inversely with disease
activity markers at 12 months. A priori, one would not
expect high levels of CXCL13 to correlate inversely with
disease parameters. Rosengren et al. [11] described plasma
CXCL13 levels to decrease in accordance with disease ac-
tivity, indicating CXCL13 and disease parameters to be
positively correlated. However, Rosengren et al. examined
patients with established RA. Bugatti et al. [15] find fewer
patients in clinical remission after one year of treatment, if
baseline levels of CXCL13 were high. In line with Bugatti
et al.’s study, Meeuwsisse et al. [16] show that high
CXCL13 is associated with increased radiographic
destruction. We do not find any association with radio-
graphic progression. Our results are of course controver-
sial in comparison with both Meeuwisse et al. and Bugatti
et al.’s findings. Though the average disease duration in
our cohort is only 3 months, where disease duration in
Bugatti’s cohort is 1 year and 2 years in Meeuwisse’ cohort.
We suggest this difference is of major importance, as these
very early RA patients comprise a more uniform cohort,
because spread in disease increases significantly over time.
Our different findings can be explained by the fact that
our patients are still in the earliest phases of disease initi-
ation. Also supporting the difference in the patient co-
horts is that 67% of patients in Bugatti et al.’s article
reached low disease activity after one year, whereas this
percentage was 76 to 80% in the OPERA cohort. Again
supporting a difference is when patients are treated ag-
gressively and as early as after just 3 months of disease.
Jones et al. [12] recently showed, that CXCL13 is asso-
ciated with rheumatoid factor in RA patients, supporting
its importance in antibody production. In our cohort of
patients with very early RA, and we did not observe
CXCL13 to be associated with rheumatoid factor. Thus,
we propose that a high, plasma CXCL13 level in
treatment-naïve early RA is a possible indicator of newly
Total no of IA glucocorticoid injections; 
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Figure 5 Number of intra-articular triamcinolone injections in patients from the CXCL13-high and -low group between baseline and
two years. Aligned dot-plot of the number of intra-articular injections is presented as total number of injection between baseline and two years.
CXCL13-high DMARD + ADA (n = 27) and DMARD (n = 23), CXCL13-low DMARD + ADA (n = 10) and DMARD (n = 16). Further, the number of
intra-articular injections is stratified into number of injections before six months and between six months and 2 years (mean with SD). ADA: adalimumab;
CXCR13: C-X-C chemokine receptor type 13; DMARD: disease-modifying anti-rheumatic drug; SD: standard deviation.
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these very early RA patients have neither established a full
memory response, nor fully developed a lymphoid follicle
antigen response at this earliest stage of disease. This
would imply that the memory process to some degree
could be halted, possibly by aggressive treatment regimes.
In the DMARD + ADA treated CXCL13-high group we
do not see this inverse correlation with disease markers.
Several studies on TNF−/− mice elucidate the importance
of TNF receptors such as TNF-R1 in fully establishing an
immune response [18-20]. Thus TNF is required for
differentiation of follicular dendritic cells and an antibody
response. This could explain the lack of associations in the
DMARD + ADA treated group and reflect the difference
in treatment response between the two groups. Thus, the
DMARD + ADA-treated patients had decreased diseaseTable 3 Additional treatment in CXCL13-high and CXCL13-low
DMARD+ ADA
CXCL13-high CXC
Additional treatment 6/27, 22.2% 4/10
Number of patients in the CXCL13-high and -low group treated with additional DMARD
the treatment during the 2-year follow-up patients will be considered to be receiving
treatment/number of patients in the group. ADA: adalimumab; CXCR13: C-X-C chemokactivity after 12 months of treatment compared with the
DMARD-treated patients [13]. This supports the hypo-
thesis that adding adalimumab to the treatment regime
impairs the development of disease progression and pos-
sibly also immunologic memory, while disease progression
in the DMARD group is ongoing. We also showed that
sustained remission (measured by DAS28CRP <2.6) at
2 years of follow-up, was associated with higher baseline
CXCL13. This finding could further support that high
baseline CXCL13 may be an indicator of recent-onset and
active disease, and that an ‘open window’ for successful
treatment does exist when the disease is in its earliest
phase. We analyzed if patients with high CXCL13 simply
were treated more aggressively, and therefore achieved
sustained remission. This was not the case, as evaluated
by number of intra-articular steroid injections andgroup
DMARD
L13-low CXCL13-high CXCL13-low
, 40% 9/23, 39,1% 6/16, 37,5%
s than MTX. If sulphasalazine, hydroxychloroquine or both has been added to
additional treatment. x/y represents the number of patients receiving additional
ine receptor type 13; DMARD: disease-modifying anti-rheumatic drug.
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When we repeated the above analysis, using CRP with a
cut of 8 mg/L as a definition of remission, no difference
in baseline CXCL13 was observed. This supports the
theory that CXCL13 especially reflects joint involve-
ment, and is not just connected to CRP. Based on these
very early RA patients from the OPERA cohort, we
propose that an initial high level of CXCL13 could be a
potential indicator that the patients are more treatment-
responsive and thereby within the so-called ‘window of
opportunity’. Adding adalimumab to the treatment re-
gime seems to further improve the chance for remission
after two years, especially with high baseline CXCL13.
Our findings may therefore also contribute to the
explanation of the disease-modifying effects of early
aggressive treatment.
Conclusions
Our study suggests that plasma CXCL13 is a marker of
early inflammation in general and especially of joint in-
volvement in early RA. Early RA patients with high base-
line CXCL13 levels could form a particular patient group
whose disease is still very responsive to treatment. This
responsiveness could indicate that patients are in the earli-
est disease stage and within the ‘window of opportunity’
where they probably respond better to early aggressive
treatment than patients whose disease has progressed.
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